SG11201806982PA - Cinnolin-4-amine compounds and their use in treating cancer - Google Patents
Cinnolin-4-amine compounds and their use in treating cancerInfo
- Publication number
- SG11201806982PA SG11201806982PA SG11201806982PA SG11201806982PA SG11201806982PA SG 11201806982P A SG11201806982P A SG 11201806982PA SG 11201806982P A SG11201806982P A SG 11201806982PA SG 11201806982P A SG11201806982P A SG 11201806982PA SG 11201806982P A SG11201806982P A SG 11201806982PA
- Authority
- SG
- Singapore
- Prior art keywords
- compounds
- salts
- international
- astrazeneca
- pct
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
- A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662310883P | 2016-03-21 | 2016-03-21 | |
PCT/EP2017/056592 WO2017162605A1 (fr) | 2016-03-21 | 2017-03-20 | Composés cinnolin-4-amine et leur utilisation pour traiter le cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201806982PA true SG11201806982PA (en) | 2018-09-27 |
Family
ID=58361025
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201806982PA SG11201806982PA (en) | 2016-03-21 | 2017-03-20 | Cinnolin-4-amine compounds and their use in treating cancer |
Country Status (18)
Country | Link |
---|---|
US (1) | US20190099421A1 (fr) |
EP (1) | EP3433251A1 (fr) |
JP (1) | JP2019512512A (fr) |
KR (1) | KR20180127419A (fr) |
CN (1) | CN108884084A (fr) |
AR (1) | AR107937A1 (fr) |
AU (1) | AU2017237394A1 (fr) |
BR (1) | BR112018068347A2 (fr) |
CA (1) | CA3017035A1 (fr) |
CO (1) | CO2018010951A2 (fr) |
DO (1) | DOP2018000197A (fr) |
IL (1) | IL261648A (fr) |
MA (1) | MA43733A (fr) |
MX (1) | MX2018011283A (fr) |
PE (1) | PE20181895A1 (fr) |
SG (1) | SG11201806982PA (fr) |
TW (1) | TW201808939A (fr) |
WO (1) | WO2017162605A1 (fr) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111344293A (zh) * | 2017-09-20 | 2020-06-26 | 阿斯利康(瑞典)有限公司 | 1,3-二氢咪唑并[4,5-c]噌啉-2-酮化合物及其在治疗癌症中的用途 |
US20210353614A1 (en) * | 2018-03-14 | 2021-11-18 | Merck Patent Gmbh | Compounds and uses thereof to treat tumors in a subject |
KR20210061337A (ko) * | 2018-09-14 | 2021-05-27 | 수저우 잔롱 파마 리미티드 | 모세혈관확장성 운동실조증 돌연변이(ATM) 키나제의 선택적 조절제로서의 1-이소프로필-3-메틸-8-(피리딘-3-일)-1,3-디하이드로-2H-이미다조[4,5-c]신놀린-2-온 및 이의 용도 |
TW202216209A (zh) | 2020-06-24 | 2022-05-01 | 英商阿斯特捷利康英國股份有限公司 | 抗體-藥物結合物及atm抑制劑之組合 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
ATE237596T1 (de) | 1996-02-13 | 2003-05-15 | Astrazeneca Ab | Chinazolinderivate und deren verwendung als vegf hemmer |
ATE211134T1 (de) | 1996-03-05 | 2002-01-15 | 4-anilinochinazolin derivate | |
GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
CL2008000191A1 (es) * | 2007-01-25 | 2008-08-22 | Astrazeneca Ab | Compuestos derivados de 4-amino-cinnotina-3-carboxamida; inhibidores de csf-1r quinasa; su proceso de preparacion; y su uso para tratar el cancer. |
WO2012101062A1 (fr) | 2011-01-28 | 2012-08-02 | Novartis Ag | Composés bi-hétéroaryles substitués en tant qu'inhibiteurs de cdk9 et leurs utilisations |
RU2637936C2 (ru) * | 2011-05-23 | 2017-12-08 | Элан Фармасьютикалз, Инк. | Ингибиторы активности киназы lrrk2 |
NO2714752T3 (fr) * | 2014-05-08 | 2018-04-21 |
-
2017
- 2017-03-20 CN CN201780017874.XA patent/CN108884084A/zh active Pending
- 2017-03-20 SG SG11201806982PA patent/SG11201806982PA/en unknown
- 2017-03-20 US US16/086,742 patent/US20190099421A1/en not_active Abandoned
- 2017-03-20 AU AU2017237394A patent/AU2017237394A1/en not_active Abandoned
- 2017-03-20 PE PE2018001829A patent/PE20181895A1/es not_active Application Discontinuation
- 2017-03-20 KR KR1020187030086A patent/KR20180127419A/ko unknown
- 2017-03-20 MX MX2018011283A patent/MX2018011283A/es unknown
- 2017-03-20 TW TW106109172A patent/TW201808939A/zh unknown
- 2017-03-20 CA CA3017035A patent/CA3017035A1/fr not_active Abandoned
- 2017-03-20 MA MA043733A patent/MA43733A/fr unknown
- 2017-03-20 EP EP17712123.3A patent/EP3433251A1/fr not_active Withdrawn
- 2017-03-20 BR BR112018068347A patent/BR112018068347A2/pt not_active IP Right Cessation
- 2017-03-20 WO PCT/EP2017/056592 patent/WO2017162605A1/fr active Application Filing
- 2017-03-20 JP JP2018549311A patent/JP2019512512A/ja active Pending
- 2017-03-21 AR ARP170100697A patent/AR107937A1/es unknown
-
2018
- 2018-09-06 IL IL261648A patent/IL261648A/en unknown
- 2018-09-18 DO DO2018000197A patent/DOP2018000197A/es unknown
- 2018-10-12 CO CONC2018/0010951A patent/CO2018010951A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
DOP2018000197A (es) | 2018-10-15 |
PE20181895A1 (es) | 2018-12-11 |
MX2018011283A (es) | 2019-05-27 |
CO2018010951A2 (es) | 2018-10-22 |
EP3433251A1 (fr) | 2019-01-30 |
MA43733A (fr) | 2018-11-28 |
KR20180127419A (ko) | 2018-11-28 |
WO2017162605A1 (fr) | 2017-09-28 |
JP2019512512A (ja) | 2019-05-16 |
BR112018068347A2 (pt) | 2019-01-15 |
TW201808939A (zh) | 2018-03-16 |
IL261648A (en) | 2018-10-31 |
AR107937A1 (es) | 2018-06-28 |
AU2017237394A1 (en) | 2018-11-01 |
CN108884084A (zh) | 2018-11-23 |
CA3017035A1 (fr) | 2017-09-28 |
US20190099421A1 (en) | 2019-04-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201903182XA (en) | 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer | |
SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
SG11201804901WA (en) | Compounds for the treatment of cancer and inflammatory disease | |
SG11201804373VA (en) | Compositions and methods for immunooncology | |
SG11201902938TA (en) | Compounds, devices, and uses thereof | |
SG11201803686UA (en) | Prodrugs of a jak inhibitor compound for treatment of gastrointestinal inflammatory disease | |
SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
SG11201804704PA (en) | Compositions and methods for decreasing tau expression | |
SG11201808566WA (en) | Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide | |
SG11201908065YA (en) | Deuterated imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer | |
SG11201809908TA (en) | Stabilized glycopeptide antibiotic formulations | |
SG11201906222WA (en) | Jak1 selective inhibitors | |
SG11201908602UA (en) | Combination therapy for the treatment of solid and hematological cancers | |
SG11201804587QA (en) | Isoindole compounds | |
SG11201806982PA (en) | Cinnolin-4-amine compounds and their use in treating cancer | |
SG11201908691PA (en) | Compounds and methods for the treatment of parasitic diseases | |
SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
SG11201906767XA (en) | Estrogen receptor modulators | |
SG11201807523PA (en) | Ilt7 binding molecules and methods of using the same | |
SG11201806424TA (en) | Therapeutic compounds | |
SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
SG11201408509PA (en) | Racecadotril lipid compositions | |
SG11201901048VA (en) | Pharmaceutical compositions and uses directed to lysosomal storage disorders |